Home > Publications database > Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway. > print

001     300694
005     20250611143146.0
024 7 _ |a 10.1038/s41416-025-03018-0
|2 doi
024 7 _ |a pmid:40287590
|2 pmid
024 7 _ |a 0007-0920
|2 ISSN
024 7 _ |a 1532-1827
|2 ISSN
024 7 _ |a altmetric:176505136
|2 altmetric
037 _ _ |a DKFZ-2025-00874
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Trewin-Nybråten, Cassia B
|b 0
245 _ _ |a Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
260 _ _ |a Edinburgh
|c 2025
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1749645060_18023
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C020# / 2025 Jun;132(12):1158-1166
520 _ _ |a Residual disease (RD) following cytoreductive surgery is prognostic for epithelial ovarian cancer (EOC) patients. Few studies have evaluated RD and survival by tumor histotype and across continuous RD diameter.2608 individuals with stages III-IV invasive EOC diagnosed between 2013 and 2022 were identified using the Cancer Registry of Norway. In flexible parametric models, we compared excess mortality comparing RD versus no macroscopic residual disease (NMRD); systemic anti-cancer therapy was evaluated in a sub-cohort from 2019. Excess mortality was assessed across continuous RD size using restricted cubic splines.Among 1849 patients with cytoreductive surgery, survival was worse for individuals with RD (vs. NMRD), excess hazard ratio (EHR) = 2.62 (95% confidence interval = (2.27-3.01)); no heterogeneity was observed by histotype (p = 0.21). Patients with 0.1-0.4 cm RD had 2-fold higher risk of death (EHR = 2.09 (1.63-2.68)) relative to women with NMRD; ~3-fold higher risk was observed for all other categories (e.g., 0.5-0.9 cm, EHR = 2.97 (2.26-3.89); 3.0-20 cm, 2.75 (2.05-3.70)). No significant difference in three-year survival was observed across continuous RD diameter (p ≥ 0.17). NMRD was associated with better survival regardless of neoadjuvant chemotherapy.Achieving NMRD resulted in the best survival outcomes. Among patients with RD, we observed no significant difference in survival by RD diameter.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Leithe, Sigrid
|b 1
700 1 _ |a Paulsen, Torbjørn
|b 2
700 1 _ |a Langseth, Hilde
|b 3
700 1 _ |a Fortner, Renée Turzanski
|0 0000-0002-1426-8505
|b 4
|e Last author
773 _ _ |a 10.1038/s41416-025-03018-0
|0 PERI:(DE-600)2002452-6
|n 12
|p 1158-1166
|t British journal of cancer
|v 132
|y 2025
|x 0007-0920
909 C O |p VDB
|o oai:inrepo02.dkfz.de:300694
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 0000-0002-1426-8505
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CANCER : 2022
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-19
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J CANCER : 2022
|d 2024-12-19
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21